Tarceva 25 mg, 100 mg & 150 mg Film-coated Tablets

  • Name:

    Tarceva 25 mg, 100 mg & 150 mg Film-coated Tablets

  • Company:
    info
  • Active Ingredients:

    Erlotinib hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/12/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 13/12/2018

Click on this link to Download PDF directly

Roche Registration GmbH

Company Products

Medicine NameActive Ingredients
Medicine Name Alecensa 150 mg Hard Capsules Active Ingredients Alectinib hydrochloride
Medicine Name Avastin 25mg/ml concentrate for solution for infusion Active Ingredients Bevacizumab
Medicine Name CellCept 1g/5ml Powder for Oral Suspension Active Ingredients Mycophenolate Mofetil
Medicine Name CellCept 250mg Capsules Active Ingredients Mycophenolate Mofetil
Medicine Name CellCept 500mg Film-coated Tablets Active Ingredients Mycophenolate Mofetil
Medicine Name CellCept 500mg powder for concentrate for solution for infusion Active Ingredients Mycophenolate mofetil hydrochloride
Medicine Name Cotellic 20 mg film-coated tablets Active Ingredients Cobimetinib hemifumarate
Medicine Name Erivedge 150 mg Hard Capsules Active Ingredients Vismodegib
Medicine Name Esbriet 267 mg Hard Capsules Active Ingredients Pirfenidone
Medicine Name Esbriet 267 mg, 534 mg and 801 mg Film-coated Tablets Active Ingredients Pirfenidone
Medicine Name Gazyvaro 1,000 mg concentrate for solution for infusion Active Ingredients Obinutuzumab
Medicine Name Hemlibra 150 mg/mL Solution for Injection Active Ingredients Emicizumab
Medicine Name Hemlibra 30 mg/mL Solution for Injection Active Ingredients Emicizumab
Medicine Name Herceptin 150mg Powder for concentrate for solution for infusion Active Ingredients Trastuzumab
Medicine Name Herceptin 600 mg Solution for Injection in Vial Active Ingredients Trastuzumab
Medicine Name Kadcyla 100mg & 160mg powder for concentrate for solution for infusion Active Ingredients Trastuzumab emtansine
Medicine Name MabThera 100 mg and 500 mg concentrate for solution for infusion Active Ingredients Rituximab
Medicine Name MabThera 1400 mg Solution for Subcutaneous Injection Active Ingredients Rituximab
Medicine Name Mircera Solution for Injection Pre-filled Syringe Active Ingredients Methoxy polyethylene glycol-epoetin beta
Medicine Name NeoRecormon solution for injection Pre-Filled Syringe Active Ingredients Epoetin beta
Medicine Name OCREVUS 300 mg concentrate for solution for infusion Active Ingredients Ocrelizumab
Medicine Name Pegasys 135 and 180 micrograms solution for injection in pre-filled pen Active Ingredients Peginterferon alfa-2a
Medicine Name Pegasys 90, 135 and 180 micrograms solution for injection in pre-filled syringe Active Ingredients Peginterferon alfa-2a
Medicine Name Perjeta 420 mg Concentrate for Solution for Infusion Active Ingredients Pertuzumab
Medicine Name RoActemra 162 mg solution for injection in pre-filled pen Active Ingredients tocilizumab
1 - 0 of 35 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 December 2018 PIL

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision

Updated on 13 December 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

II58

Updated on 17 August 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 21 May 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Transfer of MAH from Roche Products Limited to Roche Products GmbH

Updated on 23 April 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 28 March 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 28 March 2018 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

$0$0$0$0$0$01.         NAME OF THE MEDICINALPRODUCT$0$0$0$0Tarceva 25 mg film‑coatedtablets$0$0Tarceva100 mg film‑coated tablets$0$0Tarceva150 mg film‑coated tablets$0$0$0$0$0$02.       QUALITATIVE ANDQUANTITATIVE COMPOSITION$0$0$0$0Tarceva25mg film coated tablets$0$0One Each film‑coated tablet contains25 mg erlotinib (as erlotinib hydrochloride).$0$0$0$0Tarceva100 mg film‑coated tablets$0$0Eachfilm‑coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride).$0$0$0$0Tarceva150 mg film‑coated tablets$0$0Eachfilm‑coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride).$0$0$0$0Excipients with knowneffect:$0$0$0$0Tarceva25mg film coated tablets$0$0Each 25 mg film-coated tablet contains 27.43 mgLactose monohydrate.$0$0$0$0Tarceva100 mg film‑coated tablets$0$0Each100 mg film-coated tablet contains 69.21mg Lactose monohydrate.$0$0$0$0Tarceva150 mg film‑coated tablets$0$0Each150 mg film-coated tablet contains 103.82mg Lactose monohydrate.$0$0$0$0For the full list ofexcipients, see section 6.1.$0$0$0$0$0$03.       PHARMACEUTICAL FORM$0$0$0$0Film‑coated tablet.$0$0$0$0Tarceva25mg film coated tablets$0$0White to yellowish,round, biconvex tablets with ‘T 25’ engraved on one side.$0$0$0$0Tarceva100 mg film‑coated tablets$0$0Whiteto yellowish, round, biconvex tablets with ‘T 100’ engraved on one side.$0$0$0$0Tarceva150 mg film‑coated tablets$0$0Whiteto yellowish, round, biconvex tablets with ‘T 150’ engraved on one side.$0$0$0$04.2     Posology and method of administration$0$0$0$0Tarceva treatment shouldbe supervised by a physician experienced in the use of anti-cancer therapies.$0$0$0$0Patients with Non-SmallCell Lung Cancer:$0$0EGFR mutation testingshould be performed prior to initiation of Tarceva asfirst-line or switch maintenance therapy intherapyin chemo-naïve patients with locally advanced or metastatic NSCLC.$0$0$0$0[ ... ]$0$0$0$0Patientswith hHepatic impairment:$0$0Erlotinib is eliminatedby hepatic metabolism and biliary excretion. Although erlotinib exposure wassimilar in patients with moderately impaired hepatic function (Child-Pugh score7-9) compared with patients with adequate hepatic function, caution should beused when administering Tarceva to patients with hepatic impairment. Dosereduction or interruption of Tarceva should be considered if severe adversereactions occur. The safety and efficacy of erlotinib has not been studied inpatients with severe hepatic dysfunction (AST/SGOT and ALT/SGPT> 5 x ULN).Use of Tarceva in patients with severe hepatic dysfunction is not recommended(see section 5.2).$0$0$0$0Patientswith rRenal impairment:$0$0The safety and efficacyof erlotinib has not been studied in patients with renal impairment (serumcreatinine concentration >1.5 times the upper normal limit). Based onpharmacokinetic data no dose adjustments appear necessary in patients with mildor moderate renal impairment (see section 5.2). Use of Tarceva in patients with severe renal impairment is notrecommended.$0$0$0$0[ .... ]$0$0$0$04.4     Special warnings and precautions foruse$0$0$0$0Assessment of EGFRmutation status$0$0When consideringthe use of Tarceva as a first line or maintenance treatment for locallyadvanced or metastatic NSCLC, it is important thatassessing the EGFR mutation status of a patient is determined.$0$0$0$0, it is important that aA well-validated, and robust, reliableand sensitive test with aprespecified positivity threshold and demonstratedutility for the determination of EGFR mutation status, using either tumor DNAderived from a tissue sample or circulating free DNA (cfDNA) obtained from ablood (plasma) sample, should be performed according to local medical practice.methodologyis chosen to avoid$0$0$0$0Ifa plasma-based cfDNA test is used and the result is negative for activatingmutations, perform a tissue test wherever possible due to the potentialfor false negative resultsfrom a plasma-based testorfalse positive determinations.$0$0[ ... ]$0$0$0$04.8     Undesirable effects$0$0 $0$0[ ... ]$0$0Table 1:Very common ADRs in study BR.21$0$0$0$0$0$0$0$0$0$0ErlotinibTarceva$0N=485$0$0$0$0Placebo$0N=242$0$0$0$0$0$0 $0$0[ ... ]$0$0 $0$0Table3:            Verycommon ADRs in study PA.3 (100 mg cohort)$0$0$0$0$0$0$0$0$0$0ErlotinibTarceva$0N = 259$0$0$0$0Placebo$0N = 256$0$0$0$0$0$0[ ... ]$0$0 $0$08.       MARKETING AUTHORISATIONNUMBER(S)$0$0$0$0EU/1/05/311/001$0$0EU/1/05/311/002$0$0EU/1/05/311/003$0$0$0$010.       DATE OF REVISION OF THETEXT$0$0$0$022 February 2018$0$0$0$0 $0$0 $0$0$0

Updated on 22 December 2017 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.       CLINICAL PARTICULARS

 

4.1     Therapeutic indications

 

[….]

 

Tarceva is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.

 

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.

 

[….]

 

10.       DATE OF REVISION OF THE TEXT

 

11 December 2017

 

 

Updated on 1 February 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 1 February 2016 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to date of revision

Updated on 24 January 2014 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 26 July 2013 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 2 May 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Change to appearance of the medicine

Updated on 27 June 2012 PIL

Reasons for updating

  • Change to side-effects

Updated on 1 September 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision
  • Changes to therapeutic indications
  • Change to, or new use for medicine

Updated on 27 May 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 8 July 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 5 May 2010 PIL

Reasons for updating

  • Change to, or new use for medicine

Updated on 3 June 2009 PIL

Reasons for updating

  • Change to side-effects

Updated on 13 February 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 5 February 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 13 August 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 26 March 2007 PIL

Reasons for updating

  • Change to date of revision

Updated on 12 February 2007 PIL

Reasons for updating

  • Change to how the medicine works
  • Change to further information section
  • Change to date of revision

Updated on 4 December 2006 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 28 March 2006 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 17 February 2006 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 23 September 2005 PIL

Reasons for updating

  • New PIL for new product